
doi: 10.1201/b13787-31
Cefotaxime is a third-generation or extended-spectrum cephalosporin which was developed in the 1970s and approved by the US Food and Drug Administration (FDA) in 1981. Cefotaxime is (6R,7R)-3-(acetyloxymethyl)-7- [[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-methoxyimino acetyl]amino]-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2- carboxylic acid; its formula is CHNOS, and its molecular weight is 455.46548 g/mol. The chemical structure of cefotaxime is shown in Figure 26.1.
2700 Medicine, 3000 Pharmacology, 3000 Pharmacology, Toxicology and Pharmaceutics, Toxicology and Pharmaceutics
2700 Medicine, 3000 Pharmacology, 3000 Pharmacology, Toxicology and Pharmaceutics, Toxicology and Pharmaceutics
| selected citations These citations are derived from selected sources. This is an alternative to the "Influence" indicator, which also reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | 0 | |
| popularity This indicator reflects the "current" impact/attention (the "hype") of an article in the research community at large, based on the underlying citation network. | Average | |
| influence This indicator reflects the overall/total impact of an article in the research community at large, based on the underlying citation network (diachronically). | Average | |
| impulse This indicator reflects the initial momentum of an article directly after its publication, based on the underlying citation network. | Average |
